Holen Sie sich die Stockscreener-App
435.93
0.32%
1.41
Handel nachbörslich:
434.52
-1.41
-0.32%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex Pharma stock (US92532F1003): cystic fibrosis franchise underpins valuation as investors weigh - AD HOC NEWS
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
Vertex Pharmaceuticals lays off 125 workers in RI - MSN
Vertex Pharma stock (US92532F1003): Health Canada review for new pain drug puts pipeline in focus - AD HOC NEWS
Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults - BioSpace
VRTX: Vertex Pharmaceuticals Seeks Approval for New Pain Treatme - GuruFocus
What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock? - Yahoo Finance
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - Yahoo Finance
Vertex Pharmaceuticals Earnings Call Highlights New Growth Engines - TipRanks
VRTX News | VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) - ChartMill
Vertex Pharma stock (US92532F1003): cystic fibrosis leader eyes new growth drivers after latest pipe - AD HOC NEWS
META_TITLE_QUOTE - Yahoo Finance
Vertex Pharma stock (US92532F1003): cystic fibrosis leader eyes gene-editing future - AD HOC NEWS
Vertex Pharmaceuticals’ SWOT analysis: kidney drug stock draws mixed views - Investing.com Australia
J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times - BioSpace
Vertex Pharma stock (US92532F1003): insider selling puts focus on biotech heavyweight - AD HOC NEWS
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc (VRTX) Stock Price, Trades & News - GuruFocus
Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing - Moomoo
VRTX: CF and pipeline innovation drive growth, with JOURNAVX and Povi poised for major impact - TradingView
Vertex (VRTX) CSO Mark Bunnage sells 33 shares in pre-set 10b5-1 trade - Stock Titan
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharma stock (US92532F1003): cystic fibrosis leader after solid quarterly results - AD HOC NEWS
North Dakota State Investment Board Buys Shares of 8,821 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Canada Post Corp Registered Pension Plan Has $2.94 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock (US92532F1003): focus on cystic fibrosis and expanding pipeline - AD HOC NEWS
Vertex Pharma stock (US92532F1003): institutional flows and pipeline keep focus on biotech heavyweig - AD HOC NEWS
Vertex Pharmaceuticals stock (US92532F1003): gene-editing hopes meet kidney data buzz - AD HOC NEWS
Leuthold Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
STF Management LP Lowers Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (VX1.DE) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX.VI) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by DNB Asset Management AS - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Allworth Financial LP Has $6.36 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex Pharma stock (US92532F1003): Q1 numbers, ESOP shelf and gene-editing momentum draw investor f - AD HOC NEWS
Vertex Pharmaceuticals (NASDAQ: VRTX) insider files Form 144 to sell vested shares - Stock Titan
Mark Bunnage sells shares at VRTX (NASDAQ: VRTX) in Form 144 filing - Stock Titan
FY2027 Earnings Forecast for VRTX Issued By Erste Group Bank - MarketBeat
Daiwa Securities Adjusts PT on Vertex Pharmaceuticals to $555 From $561, Maintains Buy Rating - marketscreener.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Atria Investments Inc - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 6,988 Shares - MarketBeat
Vertex (VRTX) CMO Carmen Bozic sells 6,988 shares in planned 10b5-1 trade - Stock Titan
Capital World Investors (NASDAQ: VRTX) reports 10.1% stake in Vertex - Stock Titan
Vertex Pharmaceuticals stock (US92532F1003): Shareholder approval fuels biotech momentum - AD HOC NEWS
Capital Research discloses 21.1M-share stake in Vertex (NASDAQ: VRTX) - Stock Titan
Vertex Pharma stock (US92532F1003): Shares up 1.06% to $453 amid biotech strength - AD HOC NEWS
Vertex Pharmaceuticals posts mixed Q1; investors focus on non-CF pipeline for growth - MSN
Pacer Advisors Inc. Buys 9,641 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Sells 10,154 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baader Bank Aktiengesellschaft Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Fierce Biotech Layoff Tracker 2026: Takeda takes away 4.5K roles; Valneva reduces workforce - Fierce Biotech
Vertex Pharmaceuticals (VRTX) Announces Approval of 2026 Stock a - GuruFocus
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex (NASDAQ: VRTX) investors back 2026 stock plan and written consent right - Stock Titan
Vertex Pharma stock (US92532F1003): Rockets 3.77% on strong options volume - AD HOC NEWS
Crossmark Global Holdings Inc. Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
0.67%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):